Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0OXCWY
ADC Name	AB-3A4-Val-Cit-MMAE
Synonyms	AB-3A4-vcMMAE; AB-3A4 vcMMAE; AB-3A4 Val-Cit-MMAE Click to Show/Hide
Organization	Alethia Biotherapeutics, Inc.
Drug Status	Investigative
Indication	In total 3 Indication(s) Ovarian cancer [ICD11:2C73] Investigative Prostate cancer [ICD11:2C82] Investigative Triple negative breast cancer [ICD11:2C60-2C65] Investigative
	3D MOL	2D MOL
Antibody Name	Anti-KAAG1 mAb AB-3A4		Antibody Info
Antigen Name	Kidney-associated antigen 1 (KAAG1)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	1.00-2.00	nM	SK-OV-3 cells	Ovarian serous cystadenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	1.00-2.00	nM	MDA-MB-231 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	1.00-2.00	nM	PC-3 cells	Prostate carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 nM-2.00 nM	Positive KAAG1 expression (KAAG1 +++/++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human cancer cell lines.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 nM-2.00 nM	Positive KAAG1 expression (KAAG1 +++/++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human cancer cell lines.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 nM-2.00 nM	Positive KAAG1 expression (KAAG1 +++/++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human cancer cell lines.
In Vitro Model	Prostate carcinoma	PC-3 cells		CVCL_0035

References

Ref 1	AB-3A4: A novel KAAG1-targeting antibody-drug conjugate is active in models of ovarian carcinoma, triple-negative breast cancer and castration-resistant prostate cancer. Cancer Res (2014) 74 (19_Supplement): 666.